Novartis Reports Results of Xolair (omalizumab) in Two P-III Studies for Chronic Rhinosinusitis with Nasal Polyps in Adults
Shots:
- The P-III POLYP 1 & POLYP 2 studies results involve assessing of Xolair (SC- q2w/q4w) vs PBO in 138 & 127 patients with CRSwNP with inadequate response to intranasal corticosteroids respectively
- The P-III POLYP 1 & POLYP 2 studies resulted in meeting its 1EPs & 2EPs- i.e- change in Nasal Polyp Score (NPS) & Nasal Congestion Score (NCS) @24wks. and is well tolerated
- Xolair is a biologic targeting IgE resulted in reducing the amount of free IgE and is approved in 90+ countries including the US & EU for moderate-to-severe or severe persistent allergic asthma- jointly developed & promoted by Novartis & Genentech in the US
Ref: Novartis | Image: Pharmafile
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com